<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366534">
  <stage>Registered</stage>
  <submitdate>21/06/2014</submitdate>
  <approvaldate>27/06/2014</approvaldate>
  <actrnumber>ACTRN12614000681651</actrnumber>
  <trial_identification>
    <studytitle>Safety, Pharmacokinetics and Pharmacodynamics of ALD403</studytitle>
    <scientifictitle>A Placebo-Controlled Trial to Determine the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of ALD403, a Humanized Anti-(Calcitonin Gene-Related Peptide) Monoclonal Antibody in Healthy Volunteers</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym>Nil</trialacronym>
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Migraine</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Group A: ALD403 C1 process-derived  100 mg administered subcutaneously (SC) in the anterior abdominal wall on Days 1, 29,  57
Group B: ALD403 C2 process-derived 100 mg administered subcutaneously (SC) in the anterior abdominal wall on Days 1, 29, 57
Doses will be administered by study personnel at site visits.

</interventions>
    <comparator>Group C: Placebo for injection administered SC in the anterior abdominal wall Days 1, 29, 57
Group D: Placebo saline administered SC in the anterior abdominal wall Days 1, 29, 57
</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Vital Signs, Clinical Laboratory tests (hematology, chemistry) to assess safety of ALD403</outcome>
      <timepoint>Baseline, Days 1, 7, 15, 29, 35, 42, 57, 63,  70, 84, 140, 196</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>ECG to assess safety of ALD403</outcome>
      <timepoint>Baseline, Days 1, 29, 57,  84, 140, 196</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of adverse events such as dizziness, rash and/or pain at injection site, headache; assessed by Principal Investigator.</outcome>
      <timepoint>Baseline throughout study to Day 196</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of ALD403</outcome>
      <timepoint>The concentrations of free ALD403 will be measured in plasma from all subjects in Groups A and B using a validated assay method after Dose 1, Dose 2, and Dose 3 and Day 70, Day 84, Day 140, and Day 196</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamics of ALD403 will be assessed by changes in forearm skin blood flow induced by topical capsaicin application and measured by a PeriCam blood perfusion imager.</outcome>
      <timepoint>Baseline, Days 1, 29, 42, 57, 70, 84, 140, 196.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Women of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception 
Willing, committed, and able to comply with scheduled clinic visits and complete all trial-related procedures
Normal renal function as calculated by the Cockcroft-Gault equation at screening
Body Mass Index (BMI) between 18.0 and 30.0 kg/m2, and a total body weight of 50 to 100 kg inclusive
No history or presence of any other medical illness Ex-smoker (&gt;6 months from quitting) or non-smoker
Agree not to post any personal medical data related to the trial or information related to the trial on any website or social media site (e.g., Facebook, Twitter) until the trial has been completed
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>History of febrile illness within 5 days prior to dosing
Clinically significant laboratory findings 
Any ongoing co-morbidity or dermatological condition The presence of tattoos on the forearm, chest, or abdominal region Any medical condition that could put the patient at increased risk with exposure to an anti-CGRP antibody such as pre-existing cardiovascular (hypertension, ischemic heart disease), cerebrovascular disease, diabetes, or Raynauds disease
Onset of a new exercise routine or major change to a previous exercise routine within 2 weeks prior to screening visit. Subjects must be willing to refrain from unusually strenuous exercise for the duration of the trial
Hospitalization for any reason within 30 days of the screening visit
History of or positive human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), and/or Hepatitis C antibody (HCV) at screening
History of malignancy other than adequately treated carcinoma in-situ of the cervix, or adequately treated, non-metastatic squamous or basal cell carcinoma of the skin within five years prior to screening  
History of past or current habitual drug abuse, including alcohol abuse History of rubber/latex allergy, or allergy to medical adhesives
History of capsaicin allergy
Known sensitivity to any of the components of the Investigational Product formulation
Receipt of any experimental, unregistered therapy (within or outside a clinical trial) within 30 days or 5 plasma half-lives (whichever is longer) before dosing
Receipt of monoclonal antibody treatment within 6 months of screening (within or outside a clinical trial)
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/07/2014</anticipatedstartdate>
    <actualstartdate>2/07/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate>18/08/2014</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Alder Biopharmaceuticals</primarysponsorname>
    <primarysponsoraddress>11804 North Creek Parkway South
Bothell WA USA 98011</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Alder Biopharmaceuticals</fundingname>
      <fundingaddress>11804 North Creek Parkway South
Bothell WA USA 98011</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Purpose:
To determine the safety of multiple subcutaneous (SC) injections ALD403 compared to placebo  in healthy female and male subjects.
To determine the pharmacokinetics, pharmacodynamics, and immunogenicity of ALD403 compared to placebo in healthy female and male subjects.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>The Alfred Hospital
55 Commercial Road
Melbourne Victoria 3004</ethicaddress>
      <ethicapprovaldate>1/08/2013</ethicapprovaldate>
      <hrec>294/13</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Jason Lickliter </name>
      <address>Nucleus Network Limited
Level 5 Burnet Institute, AMREP Precinct
89 Commercial Rd
Melbourne, VIC 3004
 
</address>
      <phone>+61 (0)3 9076 8906</phone>
      <fax>+61 (0)3 9076 8911</fax>
      <email>J.Lickliter@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Sarah Wilson</name>
      <address>Nucleus Network Limited
Level 5 Burnet Institute, AMREP Precinct
89 Commercial Rd
Melbourne, VIC 3004
</address>
      <phone>+61 (0)3 9076 8909</phone>
      <fax />
      <email>S.Wilson@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Sarah Wilson</name>
      <address>Nucleus Network Limited
Level 5 Burnet Institute, AMREP Precinct
89 Commercial Rd
Melbourne, VIC 3004</address>
      <phone>+61 (0)3 9076 8909</phone>
      <fax />
      <email>S.Wilson@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>